Filter Releases
 
Press Releases
Date Title and Summary View
Aug 2, 2016
WALTHAM, Mass., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone responsive metastatic breast cancer, and other postmenopausal conditions including vasomotor symptoms, today announced that President an...
Jul 20, 2016
WALTHAM, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced today that it will present new data from multiple studies of abaloparatide ...
Jul 15, 2016
WALTHAM, Mass., July 15, 2016 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its second quarter 2016 financial results on Thursday, August 4, 2016. In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 8:00 a.m. ET on Th...
Jul 5, 2016
WALTHAM, Mass., July 05, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone responsive metastatic breast cancer, and other postmenopausal conditions including vasomotor symptoms, today announced that Chief Commer...
Jun 1, 2016
WALTHAM, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone responsive metastatic breast cancer, and other postmenopausal conditions including vasomotor symptoms, today announced that President and ...
May 31, 2016
WALTHAM, Mass., May 31, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that its New Drug Application (NDA) for abaloparatide—SC has b...
May 13, 2016
WALTHAM, Mass., May 13, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced that, on May 8, 2016, the compensation committee of the company's board of di...
May 5, 2016
Radius submitted an NDA to the US FDA for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis and reduction of fracture risk.  An MAA for abaloparatide-SC is currently under regulatory review by the European Medicines Agency and we expect a CHMP scientific opinion...
May 2, 2016
WALTHAM, Mass., May 02, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone responsive metastatic breast cancer, and other postmenopausal conditions including vasomotor symptoms, today announced that President and C...
Apr 21, 2016
WALTHAM, Mass., April 21, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases today announced that President and Chief Executive Officer, Robert E. Ward, will present at t...
Apr 15, 2016
-Highlights from Phase 3 ACTIVE and ACTIVExtend Trials--New Results from WHO FRAX® assessment of ACTIVE Trial demonstrate consistency of fracture risk reduction--WCO-IOF-ESCEO Malaga 2016 is the largest forum for clinical research and edu...
Apr 12, 2016
WALTHAM, Mass., April 12, 2016 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its first quarter 2016 financial results on Thursday, May 5, 2016. In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 8:00 a.m. ET on Thursday, May 5, 2016...
Apr 1, 2016
WALTHAM, Mass., April 01, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced that, on March 28, 2016, the compensation committee of the company's board ...
Apr 1, 2016
WALTHAM, Mass., April 01, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced results from pre-specified subgroup analyses from its Phase 3 ACTIVE trial. The results d...
Mar 30, 2016
— Significant Reduction in the Risk of Vertebral, Nonvertebral, Clinical and Major Osteoporotic Fractures and Increases in Bone Mineral Density in Phase 3 Studies — — If approved, abaloparatide-SC would be the first new bone anabolic in the US since 2002...
= add release to Briefcase